Johnson &amp; Johnson stock jumps 8% after it says human testing of its coronavirus vaccine to begin by September  Johnson &amp; Johnson stock climbed 8% Monday after the company said human testing of its experimental vaccine for the coronavirus will begin by September and it could be available for emergency use authorization in early 2021 .
J&amp;J 's lead vaccine candidate will enter a phase 1 human clinical study by September , the company said , and clinical data on its effects is expected before the end of the year .
The company said it is also increasing its manufacturing capacity with a new site in the U .
and additions to existing sites in other countries to produce and distribute the potential vaccine quickly .
Johnson &amp; Johnson stock climbed 8% Monday after the company said human testing of its experimental vaccine for the coronavirus will begin by September and it could be available for emergency use authorization in early 2021 .
J&amp;J also said it has committed more than $1 billion of investment in partnership with the federal Biomedical Advanced Research and Development Authority , which is part of the Department of @ @ @ @ @ @ @ @ @ @  J&amp;J 's lead vaccine candidate will enter a phase 1 human clinical study by September , the company said , and clinical data on its effects is expected before the end of the year .
If the vaccine works well , the company said it could be available for emergency use in early 2021 .
The company said it is also increasing its manufacturing capacity with a new site in the U .
and additions to existing sites in other countries to produce and distribute the potential vaccine quickly .
J&amp;J said it seeks to produce more than 1 billion doses of the potential vaccine .
" We have very good early indicators that not only can we depend on this to be a safe vaccine base but also one that will ultimately be effective based on all the early testing and modelling we 've been doing , " Chairman and CEO Alex Gorsky said Monday on CNBC 's " Squawk Box .
" " This is a bit of a moonshot for J&amp;J going forward , but it 's one we feel is very , very important @ @ @ @ @ @ @ @ @ @ .
"  Gorsky added that the company is pursuing the vaccine on a " not-for-profit basis , " but he declined to estimate how much it could cost the consumer .
On top of a lead vaccine candidate , J&amp;J said it has two back-ups .
The company said it began working on COVID-19 vaccine development in January .
J&amp;J said the pace at which it expects to develop a vaccine is faster than the typical five to seven years .
Global efforts are underway to develop a vaccine for the virus that has killed over 34,000 worldwide , but experts have cautioned it could take over a year to have one ready .
A patient was dosed with Moderna 's vaccine in an early-stage trial earlier this month , making it the front-runner in the race to develop a viable vaccine .
According to the World Health Organization , another candidate from China-based CanSino Biological is also in a phase 1 trial .
Without a vaccine , some health authorities are using Gilead Sciences ' antiviral drug Remdesivir , which was tested as a @ @ @ @ @ @ @ @ @ @ Centers for Disease Control and Prevention Robert Redfield said earlier this month that the drug is being used in Washington state to treat COVID-19 patients .
